Cocaine, Other Psychostimulants, and Hallucinogens¶

Chapter 468 | Part 13: Neurologic Disorders

KEY CLINICAL POINTS¶

Cocaine and other psychostimulants (e.g., methamphetamine, MDMA) act via dopamine reuptake inhibition, leading to euphoria, increased alertness, and cardiovascular effects.
Epidemiology: 5 million U.S. adults used cocaine in 2023; 2.6 million used hallucinogens; overdose deaths involving cocaine rose 5.6-fold from 2011 to 2022.
Acute cocaine toxicity includes sympathetic overactivity (hypertension, tachycardia, arrhythmias), while chronic use causes cardiovascular damage (LVH, cardiomyopathy).
Psychostimulant use disorders require multimodal treatment: behavioral therapies (CBT, contingency management) and emerging pharmacologic agents (e.g., lisdexamfetamine).
Emerging drugs like synthetic cathinones (bath salts) and fentanyl adulterants pose significant overdose risks due to unpredictable potency and cross-tolerance.

1. DEFINITION & OVERVIEW¶

Psychostimulants (cocaine, methamphetamine, MDMA, cathinones) and hallucinogens (LSD, PCP, psilocybin) alter CNS function via monoamine neurotransmitter modulation. Cocaine is a Schedule II drug with local anesthetic and vasoconstrictor properties. Hallucinogens disrupt serotonin and glutamate systems, causing perceptual and cognitive distortions.

1.1 Pharmacology¶

Cocaine inhibits dopamine (DA), norepinephrine (NE), and serotonin (5HT) reuptake. Methamphetamine enhances DA release via vesicular monoamine transporter (VMAT) and inhibits monoamine oxidase (MAO). MDMA binds serotonin transporters and increases monoamine release. Hallucinogens (e.g., LSD) act on 5-HT2A receptors.

1.2 Clinical Spectrum¶

Acute effects: euphoria, hyperactivity, hypertension. Chronic effects: cardiovascular damage, neurotoxicity, and psychiatric comorbidities. Polydrug use (e.g., cocaine + opioids) increases mortality risk.

2. EPIDEMIOLOGY¶

According to NSDUH 2023: 5 million U.S. adults (1.8%) used cocaine; 2.6 million used hallucinogens. Cocaine-related overdose deaths rose 5.6-fold (1.5 to 8.2 per 100,000) from 2011 to 2022. Synthetic opioids (e.g., fentanyl) and xylazine contribute to rising mortality.

2.1 Demographics¶

Cocaine use peaks in 18–25-year-olds; MDMA use is more common among gay/bisexual men. Synthetic cathinones are prevalent in Central Asia and Eastern Europe.

2.2 Risk Factors¶

Genetic predisposition, trauma, mental health comorbidities (e.g., ADHD, PTSD), and socioeconomic disadvantage increase vulnerability. Polydrug use (e.g., cocaine + alcohol) exacerbates toxicity.

3. ETIOLOGY & PATHOPHYSIOLOGY¶

Cocaine blocks DA reuptake, increasing synaptic levels and causing hyperactivation of CNS. Methamphetamine induces dopamine release via VMAT and inhibits MAO. Hallucinogens (e.g., LSD) activate 5-HT2A receptors, altering perception and cognition. Chronic use leads to neuroadaptations, including receptor downregulation and neurotoxicity.

3.1 Neurotransmitter Mechanisms¶

Cocaine: DA, NE, 5HT reuptake inhibition. Methamphetamine: VMAT2 activation, MAO inhibition. MDMA: Serotonin transporter binding, monoamine release. Hallucinogens: 5-HT2A receptor agonism.

3.2 Neurotoxicity¶

Chronic use causes dopaminergic neuron damage, glutamate excitotoxicity, and oxidative stress. Cocaine-induced neuroinflammation contributes to cognitive deficits and addiction.

4. CLINICAL FEATURES¶

Acute effects: sympathetic overactivity (hypertension, tachycardia), hallucinations, and CNS stimulation. Chronic effects: cardiovascular damage (LVH, cardiomyopathy), psychosis, and cognitive impairment. Overdose presents with arrhythmias, hyperthermia, and multiorgan failure.

4.1 Acute Toxicity¶

Sympathomimetic effects: hypertension, tachycardia, arrhythmias. Psychotic features: paranoia, hallucinations. Pulmonary: bronchospasm, pneumothorax. Gastrointestinal: ulceration, perforation.

4.2 Chronic Complications¶

Cardiovascular: LVH, cardiomyopathy. Neurological: cognitive deficits, Parkinsonism. Psychiatric: depression, anxiety, psychosis. Endocrine: hyperprolactinemia, gynecomastia.

5. DIFFERENTIAL DIAGNOSIS¶

Differentiate from other stimulants (e.g., amphetamines), hallucinogen-induced psychosis, and neuroleptic malignant syndrome. Consider comorbid mental health disorders (e.g., bipolar disorder, schizophrenia) and substance-induced delirium.

5.1 Psychotic Disorders¶

Hallucinogen-induced psychosis vs. schizophrenia: duration, precipitating factors, and response to antipsychotics.

5.2 Cardiovascular Emergencies¶

Cocaine-induced myocardial infarction vs. STEMI: ECG findings, troponin levels, and response to reperfusion therapy.

6. INVESTIGATIONS & DIAGNOSIS¶

Diagnostic criteria: DSM-5 stimulant use disorder ( ≥ 2 of 11 criteria). Laboratory tests: urine toxicology, CBC, electrolytes, troponin, and ECG. Imaging: chest X-ray for pulmonary embolism or infiltrates.

6.1 Diagnostic Criteria¶

DSM-5: Impairment in daily functioning, tolerance, withdrawal, and compulsive use. ICD-11: Stimulant dependence including amphetamines, methamphetamines, or methcathinone.

6.2 Toxicology Screening¶

Urine tests for cocaine, amphetamines, MDMA, and synthetic cathinones. Blood tests for fentanyl, xylazine, and other adulterants.

7. MANAGEMENT & TREATMENT¶

First-line: behavioral therapies (CBT, contingency management). Pharmacologic options: naltrexone, bupropion, and emerging agents (e.g., lisdexamfetamine). Acute overdose: benzodiazepines, beta-blockers (avoid in cocaine toxicity), and supportive care.

7.1 Acute Intoxication¶

Airway management, benzodiazepines for agitation, and intravenous fluids. Avoid beta-blockers in cocaine overdose. Monitor for arrhythmias and hyperthermia.

8. PROGNOSIS & COMPLICATIONS¶

Chronic use leads to progressive cardiovascular damage, cognitive decline, and psychiatric comorbidities. Overdose mortality is high, especially with polydrug use. Long-term survivors may experience persistent neurocognitive deficits.

8.1 Mortality¶

Cocaine-related deaths: 36,251 in 2023. Synthetic opioids (e.g., fentanyl) contribute to 60% of stimulant-related fatalities.

8.2 Neurological Outcomes¶

Chronic users may develop Parkinsonism, cognitive impairment, and white matter changes. Hallucinogen-induced psychosis can persist for months.

9. SPECIAL CONSIDERATIONS¶

Pregnancy: Cocaine use increases preterm birth and fetal growth restriction. Pediatrics: ADHD and stimulant misuse in children. Elderly: Increased cardiovascular risk. LGBTQ+ populations: Higher rates of MDMA use and mental health comorbidities.

9.1 Pregnancy¶

Cocaine use linked to placental abruption, fetal growth restriction, and neonatal abstinence syndrome.

9.2 Vulnerable Populations¶

Homeless individuals and those with SUDs face higher overdose risks. Stigma and socioeconomic barriers hinder treatment access.

10. KEY POINTS & CLINICAL PEARLS¶

Cocaine overdose requires immediate airway management and avoidance of beta-blockers.
Synthetic cathinones (bath salts) are potent and unpredictable.
Behavioral therapies are the cornerstone of long-term recovery.
Monitor for cardiovascular complications in all stimulant users.

Table 468-1 Complications of Psychostimulant Use¶

Category	Acute	Chronic
Cardiovascular	Arterial vasoconstriction, tachycardia, hypertension	Accelerated atherogenesis, LVH, dilated cardiomyopathy
Neurological	Hyperthermia, seizures, coma	Cognitive deficits, Parkinsonism
Gastrointestinal	Ulcers, perforation	Ischemic colitis, bowel infarction
Renal	Rhabdomyolysis, metabolic acidosis	Renal infarction
Endocrine	Hyperprolactinemia, gynecomastia	Impotence, menstrual dysfunction